Engineering antibodies for conditional activity in the solid tumor microenvironment

Area of Science:

• Oncology
• Biotechnology
• Protein Engineering

Background:

• Antibody therapeutics are successful cancer treatments but cause toxicities by targeting antigens in healthy tissues.
• These toxicities limit antibody use in some patients and therapeutic approaches.
• Developing targeted antibody therapies is crucial for expanding treatment options.

Purpose of the Study:

• To review strategies for engineering antibody therapeutics with activity restricted to the tumor microenvironment.
• To decrease toxicities and broaden the therapeutic window of antibody-based cancer treatments.
• To explore novel targeting mechanisms for enhanced precision medicine.

Main Methods:

• Protein engineering strategies to create antibodies sensitive to tumor-specific characteristics.
• Utilizing intrinsic tumor microenvironment triggers: low pH, high extracellular ATP, and specific proteases.
• Employing exogenous triggers like light and ultrasound for spatial and temporal control of antibody activation.

Main Results:

• Engineered antibodies demonstrate tumor-specific binding and activity.
• Reduced off-tumor recognition and associated toxicities observed.
• Expanded therapeutic potential by overcoming previous limitations.

Conclusions:

• Advanced antibody engineering strategies can restrict therapeutic activity to the tumor microenvironment.
• Multilayered targeting approaches promise a new era of precision cancer therapeutics.
• These innovations aim to improve safety profiles and treatment efficacy for a wider patient population.